首页> 外文OA文献 >Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer

【2h】

Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer

机译：帕妥珠单抗联合曲妥珠单抗和多西紫杉醇在HER2 +早期乳腺癌新辅助治疗中的药代动力学和暴露-反应分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. PHARMACOKINETIC AND EXPOSURE-RESPONSE ANALYSES OF PERTUZUMAB PLUS TRASTUZUMAB AND DOCETAXEL DURING NEOADJUVANT TREATMENT OF HER2+EARLY BREAST CANCER. [J] . Quartino A. L., Li H., Jin J. Y., Clinical Pharmacology and Therapeutics . 2014,第Suppla1期

机译：HER2 +早期乳腺癌新辅助治疗期间帕妥珠单抗加曲妥珠单抗和多西他赛的药代动力学和暴露反应分析。
2. PHARMACOKINETIC AND EXPOSURE-RESPONSE ANALYSES OF PERTUZUMAB PLUS TRASTUZUMAB AND DOCETAXEL DURING NEOADJUVANT TREATMENT OF HER2+EARLY BREAST CANCER [J] . Quartino A. L., Li H., Jin J. Y., Clinical Pharmacology and Therapeutics . 2014,第Suppla1期

机译：HER2 +早期乳腺癌新辅助治疗过程中帕妥珠单抗加曲妥珠单抗和多西他赛的药代动力学和暴露反应分析
3. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer [J] . Giampaolo Bianchini, Astrid Kiermaier, Giulia Valeria Bianchi, Breast Cancer Research . 2017,第1期

机译：NeoSphere研究的生物标志物分析：帕妥珠单抗，曲妥珠单抗和多西他赛与曲妥珠单抗加多西他赛，帕妥珠单抗加曲妥珠单抗或帕妥珠单抗加多西他赛用于HER2阳性乳腺癌的新辅助治疗
4. Breast MRI radiomics for the pre-treatment prediction of response to neoadjuvant chemotherapy in node-positive breast cancer patients [C] . Karen Drukker, Iman El-Bawab, Alexandra Edwards, SPIE Conference on Computer-Aided Diagnosis . 2019

机译：乳腺MRI辐射射清，用于节点阳性乳腺癌患者对新辅助化疗的反应预处理预测
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer [O] . Angelica L. Quartino, Hanbin Li, Jin Y. Jin, -1

机译：帕妥珠单抗联合曲妥珠单抗和多西紫杉醇在HER2 +早期乳腺癌新辅助治疗中的药代动力学和暴露-反应分析
7. Cost-Utility Analysis of Neoadjuvant Chemotherapy with Pertuzumab, Trastuzumab and Docetaxel in Patients With HER2+ Breast Cancer in Spaincost-Utility Analysis of Neoadjuvant Chemotherapy with Pertuzumab, Trastuzumab and Docetaxel in Patients With HER2+ Breast Cancer in Spain [O] . R Colomer, E Ciruelos, J De la Haba, 2016

机译：西班牙治疗腹膜康氏症患者腹膜癌患者腹膜癌，胸瘤和多西紫杉醇患者腹膜癌患者的新辅助化疗的成本实用性分析

Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer

著录项

引文网络

相似文献

相关主题

期刊订阅